Ibex Investors’s Charles River Laboratories CRL Stock Holding History

Ibex Investors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,916	Closed	-$217K	–	73
2018 Q4	$217K	Buy	+1,916	New	+$240K	0.04%	121

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Ibex Investors's CRL Position: Q1 2019 in Review

Ibex Investors sold out of Charles River Laboratories (CRL) in Q1 2019, closing a stake of 1,916 shares — an estimated $217K sold.

Ibex Investors first reported a position in CRL in Q4 2018 and held it in 1 quarter. The position peaked at $217K in Q4 2018. 409 funds tracked by Wall St. Rank hold CRL as of Q1 2019.

Ibex Investors reported no remaining Charles River Laboratories position as of Q1 2019 after selling out during the quarter.
Ibex Investors sold 1,916 Charles River Laboratories shares in Q1 2019, an estimated $217K.
Ibex Investors first reported a position in Charles River Laboratories in Q4 2018 and held it in 1 quarter.
Ibex Investors's Charles River Laboratories position peaked at $217K in Q4 2018.
409 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2019.

Based on Ibex Investors's 13F filing for Q1 2019, filed 7 May 2019.